Icad Stock Price, News & Analysis
Company Description
iCAD, Inc. (formerly NASDAQ: ICAD) is a medical technology company focused on applying artificial intelligence to breast health. According to the company’s public disclosures, iCAD’s mission is to help create a world where cancer cannot hide by providing clinically proven AI-powered solutions that enable medical providers to detect cancer earlier and improve patient outcomes. The company has described itself as a global leader in clinically proven AI-powered cancer detection and breast health solutions, with technology used by thousands of providers and available in numerous countries.
Headquartered in Nashua, New Hampshire, iCAD develops and commercializes the ProFound Breast Health Suite, which the company characterizes as an industry-leading platform for AI-powered mammography analysis. This suite supports breast cancer detection, density assessment, and risk evaluation. iCAD has reported that ProFound is used by providers serving millions of patients and that, over a recent five-year period, its technology was used to read tens of millions of mammograms worldwide, including a significant proportion of digital breast tomosynthesis exams.
The ProFound Breast Health Suite incorporates deep learning and AI-based image analysis designed to assist radiologists in interpreting mammograms. Company communications emphasize applications in early breast cancer detection, assessment of breast density, and evaluation of short- and longer-term breast cancer risk. iCAD also highlights research and clinical collaborations that explore AI-based breast arterial calcification assessment and other breast health indicators, reflecting an emphasis on personalized risk assessment and workflow optimization in breast imaging.
In addition to on-premise deployments, iCAD is transitioning its offerings toward a software-as-a-service and cloud-based delivery model. The company has described new cloud-hosted platforms, such as ProFound Cloud, intended to provide fast, flexible, and scalable access to its AI solutions for healthcare providers worldwide. This transition is reflected in the company’s reported growth in annual recurring revenue and in the increasing number of cloud deals closed with customers.
iCAD’s technology is integrated into broader radiology ecosystems through partnerships with imaging and health technology companies. Public announcements describe collaborations that embed the ProFound Breast Health Suite into radiology information systems, picture archiving and communication systems, and cloud-based precision imaging networks. These integrations are intended to place AI-generated insights directly into radiologists’ existing workflows, supporting screening, diagnosis, and reporting in breast imaging.
Clinical research is a central part of iCAD’s positioning. The company regularly highlights abstracts and presentations at major radiology and oncology conferences that evaluate its AI tools for breast cancer detection, short-term and long-term risk prediction, and breast arterial calcification assessment across diverse populations. These studies, led by research collaborators, are presented as evidence of the potential for AI to enhance early detection, support primary prevention strategies, and address disparities in breast cancer screening and outcomes.
Historically, iCAD’s business has been reported in terms of product and services revenue, with a strategic shift toward recurring revenue through subscriptions and cloud offerings. The company has disclosed high gross margins characteristic of software- and AI-based solutions and has emphasized the importance of annual recurring revenue as a key performance indicator during its transition to a SaaS-oriented model.
As of mid-2025, iCAD’s corporate structure changed significantly. A Form 15 filed with the U.S. Securities and Exchange Commission states that, on July 17, 2025, Trio Merger Sub, Inc., a wholly owned subsidiary of RadNet, Inc., merged with and into iCAD, with iCAD surviving as a wholly owned subsidiary of RadNet. In connection with this transaction, iCAD’s common stock ceased to be registered under Section 12(g) of the Securities Exchange Act of 1934, and its duty to file certain periodic reports was suspended. A related Form 8-K details that iCAD stockholders approved the merger agreement with RadNet at a special meeting held on July 14, 2025.
Following this merger, iCAD no longer trades as an independent public company under the ICAD ticker. Instead, it operates as part of RadNet’s broader diagnostic imaging and digital health portfolio. For investors and researchers, ICAD now represents the historical trading symbol and public-company record for iCAD, Inc. prior to its acquisition by RadNet.
Business focus and technology
Based on the company’s own descriptions, iCAD’s core activities center on:
- AI-powered mammography analysis through the ProFound Breast Health Suite, supporting detection of breast cancer, breast density assessment, and risk evaluation.
- Deep learning and AI research applied to breast imaging, including risk models derived from mammographic data and tools for assessing breast arterial calcifications.
- Cloud and SaaS delivery of breast imaging AI solutions, including ProFound Cloud, to expand access for healthcare providers globally.
- Workflow integration via partnerships with radiology software and cloud platforms, embedding AI results into existing reporting and imaging systems.
Corporate status and historical context
ICAD as a ticker symbol historically referred to iCAD, Inc., a Delaware corporation whose common stock was listed on The NASDAQ Stock Market LLC. According to the company’s Form 8-K dated July 14, 2025, stockholders approved an Agreement and Plan of Merger with RadNet, Inc. and Trio Merger Sub, Inc. The subsequent Form 15 filed on July 28, 2025, confirms that, as of July 17, 2025, Trio Merger Sub merged with and into iCAD, with iCAD surviving as a wholly owned subsidiary of RadNet. As a result, iCAD terminated the registration of its common stock and suspended its reporting obligations under the Exchange Act.
For users researching ICAD, this means that the symbol now serves as a historical reference to iCAD’s period as an independent public company. Current information about the business and its breast health AI solutions is expected to be reflected within RadNet’s corporate and financial disclosures.